[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2015509360A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509360A5
JP2015509360A5 JP2014556093A JP2014556093A JP2015509360A5 JP 2015509360 A5 JP2015509360 A5 JP 2015509360A5 JP 2014556093 A JP2014556093 A JP 2014556093A JP 2014556093 A JP2014556093 A JP 2014556093A JP 2015509360 A5 JP2015509360 A5 JP 2015509360A5
Authority
JP
Japan
Prior art keywords
cells
population
tissue
human
syndecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556093A
Other languages
English (en)
Other versions
JP2015509360A (ja
JP5829765B2 (ja
Filing date
Publication date
Priority claimed from GBGB1202319.8A external-priority patent/GB201202319D0/en
Application filed filed Critical
Publication of JP2015509360A publication Critical patent/JP2015509360A/ja
Publication of JP2015509360A5 publication Critical patent/JP2015509360A5/ja
Application granted granted Critical
Publication of JP5829765B2 publication Critical patent/JP5829765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (21)

  1. 哺乳類間質幹細胞の集団であって、該細胞の30%またはそれ以上がSyndecan−2について陽性である、細胞の集団。
  2. 前記細胞がマウス、ラット、ウマまたはヒト細胞である、請求項1に記載の細胞の集団。
  3. 前記細胞がヒト細胞である、請求項2に記載の細胞の集団。
  4. 前記細胞の40%またはそれ以上がSyndecan−2について陽性である、請求項1からのいずれかに記載の細胞の集団。
  5. 前記細胞の50%またはそれ以上がSyndecan−2について陽性である、請求項1からのいずれかに記載の細胞の集団。
  6. 前記細胞の75%またはそれ以上がSyndecan−2について陽性である、請求項1から5のいずれかに記載の細胞の集団。
  7. 間質幹細胞の単離方法であって、Syndecan−2の発現に基づき哺乳類細胞の混合集団から細胞を単離する工程を含、方法。
  8. ヒト細胞の単離のための、請求項に記載の方法。
  9. マウス、ラットまたはウマ細胞の単離のための、請求項に記載の方法。
  10. 前記哺乳類細胞の混合集団が、骨髄、脂肪組織、骨格筋、子宮内膜、胎盤、臍帯血、臍帯、ウォートンジェリーおよび多能性細胞由来細胞から選択される供給源から得られる、請求項からのいずれかに記載の方法。
  11. 骨形成細胞および脈管形成細胞の単離のための、請求項10に記載の方法。
  12. 間質細胞の単離のための、請求項7から11のいずれかに記載の方法であって、それらの単離された細胞から細胞の集団を誘導する工程をさらに含む、方法。
  13. 細胞のクローン性集団を得る方法であって、請求項から11のいずれかに記載の方法に従って単一細胞を単離する工程;および該単一細胞から細胞のクローン性集団を誘導する工程を含む、方法。
  14. 組織を得る方法であって、請求項7から13のいずれかに従って細胞を得る工程、およびそこから組織を得る工程を含む、方法。
  15. 前記組織が骨である、請求項14に記載の方法。
  16. 前記組織が軟骨である、請求項14に記載の方法。
  17. 前記組織が腱である、請求項14に記載の方法。
  18. 請求項からのいずれかに記載の細胞の使用を含むアッセイ。
  19. 動物、例えば、ヒトにおいて疾患または障害を治療するための医薬組成物であって、請求項1から6のいずれかに記載の細胞を含む、組成物。
  20. 生理食塩水またはリン酸緩衝生理食塩水を含み、かつ必要に応じて、ジメチルスルホキシド、ヒト血清アルブミン、ヒアルロン酸およびコラーゲンの1つ以上もまた含む、請求項19に記載の組成物。
  21. 動物、例えば、ヒトの疾患または障害の治療に使用するための、請求項1から6のいずれかに記載の細胞
JP2014556093A 2012-02-10 2013-02-11 間質幹細胞 Active JP5829765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1202319.8A GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells
GB1202319.8 2012-02-10
PCT/EP2013/052692 WO2013117761A1 (en) 2012-02-10 2013-02-11 Stromal stem cells

Publications (3)

Publication Number Publication Date
JP2015509360A JP2015509360A (ja) 2015-03-30
JP2015509360A5 true JP2015509360A5 (ja) 2015-07-02
JP5829765B2 JP5829765B2 (ja) 2015-12-09

Family

ID=45929927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556093A Active JP5829765B2 (ja) 2012-02-10 2013-02-11 間質幹細胞

Country Status (22)

Country Link
US (10) US11230700B2 (ja)
EP (4) EP3492584B1 (ja)
JP (1) JP5829765B2 (ja)
KR (1) KR102124837B1 (ja)
CN (1) CN104302763B (ja)
AU (1) AU2013217870B2 (ja)
BR (1) BR112014019277A8 (ja)
CA (1) CA2863821C (ja)
CY (1) CY1116365T1 (ja)
DK (1) DK2758523T3 (ja)
ES (3) ES2539186T3 (ja)
GB (1) GB201202319D0 (ja)
HR (1) HRP20150594T1 (ja)
HU (1) HUE026480T2 (ja)
IN (1) IN2014KN01777A (ja)
PL (1) PL2758523T3 (ja)
PT (1) PT2758523E (ja)
RS (1) RS54073B1 (ja)
RU (1) RU2636551C2 (ja)
SI (1) SI2758523T1 (ja)
SM (1) SMT201500147B (ja)
WO (1) WO2013117761A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
KR20150143625A (ko) 2013-04-16 2015-12-23 오르브센 테라퓨틱스 리미티드 신데칸 2의 의학적 용도
US20170044497A1 (en) 2014-02-12 2017-02-16 National University Of Ireland, Galway Selection and use of stem cells
KR101690872B1 (ko) 2014-08-19 2016-12-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
US9716660B2 (en) * 2014-12-11 2017-07-25 Intel Corporation Hierarchical enforcement of service flow quotas
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−2のモジュレーターとその使用
EP3402489B1 (en) * 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
WO2018220442A2 (en) * 2017-05-30 2018-12-06 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
JP7174758B2 (ja) * 2017-07-14 2022-11-17 オーブセン セラピューティクス リミテッド Cd39間質幹細胞の単離方法と使用
JP2022548778A (ja) 2019-09-23 2022-11-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 線維芽細胞活性化タンパク質(fap)を標的とすることによる腫瘍組織の破壊の方法
WO2022179518A1 (en) * 2021-02-25 2022-09-01 Rosas Ivan O Anti-fibrotic peptides and uses thereof
CN116334214A (zh) * 2023-04-04 2023-06-27 暨南大学附属第一医院(广州华侨医院) 一种用于急性心肌梗死和稳定性心绞痛鉴别的生物标志物的ceRNA调控网络及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012403A (en) 1911-01-23 1911-12-19 Thomas W Mcneill Smoke-indicator.
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5726058A (en) 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
WO1997034605A1 (en) 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
CA2323073C (en) * 1998-03-13 2010-06-22 Osiris Therapeutics, Inc. Uses for human non-autologous mesenchymal stem cells
ATE368731T1 (de) 1998-05-29 2007-08-15 Osiris Therapeutics Inc Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
JP5090604B2 (ja) 2000-04-25 2012-12-05 オシリス セラピューティクス,インコーポレイテッド 動物の関節修復のための医薬組成物調製への間葉幹細胞の使用法
US7442390B2 (en) * 2000-06-05 2008-10-28 University Of South Florida Method for enhancing engraftment of cells using mesenchymal progenitor cells
WO2002087609A1 (en) 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
AU2003214857A1 (en) 2002-01-18 2003-09-02 Regents Of The University Of Minnesota Syndecans and angiogenesis
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
CA2547899C (en) * 2002-12-05 2014-04-15 Case Western Reserve University Cell-based therapies for ischemia
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ, インコーポレイテッド IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
JP2007530543A (ja) 2004-03-22 2007-11-01 オシリス セラピューティクス,インコーポレイテッド 間葉幹細胞及びその使用法
BRPI0514387B8 (pt) * 2004-08-16 2021-05-25 Cellresearch Corp Pte Ltd método para isolar células-tronco epiteliais ou mesenquimais/progenitoras da membrana amniótica do cordão umbilical, método in vitro para cultivar células-tronco mesenquimais/progenitoras, composição farmacêutica e uso de uma célula-tronco epitelial ou mesenquimal/progenitora
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
JP5283219B2 (ja) 2006-04-20 2013-09-04 学校法人自治医科大学 ベクター産生型腫瘍標的細胞
US20070264239A1 (en) 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
WO2008085229A2 (en) 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR100883565B1 (ko) 2007-02-14 2009-02-13 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
CA2693144A1 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CN101835889B (zh) 2007-10-17 2013-07-17 特克赛尔公司 Tr1细胞、间充质干细胞和其用途
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US20090220588A1 (en) 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
WO2010065239A1 (en) 2008-12-05 2010-06-10 Wake Forest University Health Sciences Stem cells from urine and methods for using the same
KR20100106744A (ko) 2009-03-24 2010-10-04 이화여자대학교 산학협력단 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물
WO2010119039A1 (en) 2009-04-13 2010-10-21 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
KR101301262B1 (ko) 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 TGFβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
KR101622650B1 (ko) 2009-12-31 2016-06-01 엘지디스플레이 주식회사 액정 전계 렌즈 및 이를 이용한 입체 표시 장치
KR101443478B1 (ko) 2010-03-10 2014-09-22 가부시키가이샤 투셀 간엽계 줄기 세포를 포함한 세포 제제 및 그의 제조 방법
US20130189275A1 (en) 2010-06-03 2013-07-25 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
WO2011160055A2 (en) 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
KR101309910B1 (ko) 2010-08-06 2013-09-17 이화여자대학교 산학협력단 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편
KR101317507B1 (ko) 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
CN103261407B (zh) * 2010-12-22 2016-03-02 杜兰教育基金委员会 用于识别和培养具有高度增殖潜能的多能间充质干细胞的方法
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
EP2683389B1 (en) 2011-03-11 2017-05-03 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
KR101145406B1 (ko) * 2011-07-06 2012-05-15 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
WO2013172793A1 (en) 2012-05-18 2013-11-21 Agency For Science, Technology & Research Umbilical cord mesenchymal stem cell exosomes
JP6542197B2 (ja) 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド 治療的送達小胞
KR20150143625A (ko) 2013-04-16 2015-12-23 오르브센 테라퓨틱스 리미티드 신데칸 2의 의학적 용도
US20160220613A1 (en) 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
PT3091991T (pt) 2013-12-13 2020-02-04 Swedish Stromabio Ab Composições imunomodulatórias
EP3182984B1 (en) 2014-08-18 2019-10-30 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
GB201418562D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−2のモジュレーターとその使用
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CN109071542B (zh) 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
WO2018220442A2 (en) 2017-05-30 2018-12-06 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
JP7174758B2 (ja) 2017-07-14 2022-11-17 オーブセン セラピューティクス リミテッド Cd39間質幹細胞の単離方法と使用
WO2020035741A2 (en) 2018-07-05 2020-02-20 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof
US20220288129A1 (en) 2019-08-23 2022-09-15 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use

Similar Documents

Publication Publication Date Title
JP2015509360A5 (ja)
HRP20150594T1 (hr) Stromalne matiäśne stanice
Schnabel et al. Therapeutic use of stem cells in horses: which type, how, and when?
Toupadakis et al. Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue
Taghizadeh et al. Wharton’s Jelly stem cells: future clinical applications
Kulus et al. Mesenchymal stem/stromal cells derived from human and animal perinatal tissues—origins, characteristics, signaling pathways, and clinical trials
Muttini et al. Ovine amniotic epithelial cells: In vitro characterization and transplantation into equine superficial digital flexor tendon spontaneous defects
Arkesteijn et al. Effect of coculturing canine notochordal, nucleus pulposus and mesenchymal stromal cells for intervertebral disc regeneration
Hulme et al. Cell therapy for cartilage repair
Stanco et al. Multidifferentiation potential of human mesenchymal stem cells from adipose tissue and hamstring tendons for musculoskeletal cell-based therapy
US20200291359A1 (en) Ectodermal mesenchymal stem cells and method for producing same
Calloni et al. Mesenchymal stromal cells from unconventional model organisms
US20230295572A1 (en) Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells
JP2022069524A (ja) 改良された細胞療法
Ivanovska et al. Immunophenotypical characterization of canine mesenchymal stem cells from perivisceral and subcutaneous adipose tissue by a species-specific panel of antibodies
Arrizabalaga et al. Properties of porcine adipose-derived stem cells and their applications in preclinical models
Wrona et al. Derivation and characterization of porcine vocal fold extracellular matrix scaffold
Leal Reis et al. Allogenic synovia-derived mesenchymal stem cells for treatment of equine tendinopathies and desmopathies—Proof of concept
Chang et al. The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells
Ramzgouyan et al. Differentiation of human endometrial stem cells into germ cell–Like cell in fibrin scaffold
Edaso et al. Review on applications of stem cells in veterinary therapeutic practices
Muramatsu et al. Intragraft chimerism following composite tissue allograft
JP2018501189A (ja) 骨欠損を治療するための体性幹細胞
Larson et al. Journal of Cell Science & Therapy
Martinello et al. Comparison in vivo applications between peripheral blood-derived mesenchymal stromal cells (PB-MSCs) and platlet-rich plasma (PRP) in injured tendons of sheep